Physician profile
John E Balmer
NPI 1104912476
$15,524.47
in general payments reported to CMS, 2019-2025
51 companies · $2,917 in 2025
The $2,917 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,860 · 2020: $1,090 · 2021: $2,260 · 2022: $2,528 · 2023: $2,429 · 2024: $2,441 · 2025: $2,917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,787.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,786.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,967.58 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $1,889.90 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $1,495.74 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,406.42 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $1,024.45 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $896.52 | 2021-2025 | Vraylar |
| Amgen INC. | $787.59 | 2020-2025 | Repatha, Otezla, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $694.87 | 2020-2025 | Caplyta |
| Indivior INC. | $578.83 | 2021-2025 | Sublocade |
| Biohaven Pharmaceuticals, INC. | $439.44 | 2021 | |
| Merck Sharp & Dohme LLC | $382.68 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Takeda Pharmaceuticals U.S.A., INC. | $345.05 | 2019-2024 | Glassia, Trintellix |
| Grifols USA, LLC | $299.81 | 2019-2025 | Prolastin-C Liquid |
| Bayer Healthcare Pharmaceuticals INC. | $289.08 | 2022-2024 | |
| Madrigal Pharmaceuticals | $272.71 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Balmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.